S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)María‐Victoria Mateos, Hila Magen, Michael Chu et al.|HemaSphere|2023Cited by 9
POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)Yaël C. Cohen, Hila Magen, Daniel Morillo et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 1
MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)Yaël C. Cohen, Hila Magen, Daniel Morillo et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 1
P-030 First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)Hila Magen, Yaël C. Cohen, Daniel Morillo et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 1
OA-03 Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-UpYaël C. Cohen, María-Victoria Mateos Manteca, Hila Magen et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 0